Acute Myeloid Leukemia, Myelodysplastic Syndrome
Conditions
Keywords
Primary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) induced AML.
Brief summary
The purpose of this study is to determine whether addition of AS101 to the standard chemotherapy regimen is effective in the treatment of newly diagnosed elderly (≥60) AML patients and AML transformed myelodysplastic syndrome (MDS) patients.
Detailed description
AML patients frequently develop cytopenia, which can result in life-threatening bleeding and infections. Despite the administration of prophylactic platelet transfusions, these patients remain at risk of clinically significant hemorrhage. There is a growing need for new, innovative strategies, because the outcome for AML patients, particularly for the older ones, has not substantially changed in the last three decades. Thus, novel compounds to target the tumor cell's resistance to chemotherapeutic agents are essential for the improvement of patients' prognoses. AS101 is a non-toxic, organic, tellurium-based small compound with immunomodulating properties which have previously shown bone marrow sparing effect. In addition in preclinical studies AS101 has shown synergistic effect with several cytotoxic drugs. This study will investigate the safety and efficacy of AS101 formulation in combination with the standard therapy for newly diagnosed elderly AML and AML transformed MDS patients.
Interventions
DRUGAS101
3 mg/m2 AS101 will be given intravenously (IV) three times per week.
Sponsors
BioMAS Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Confirmed diagnosis of primary AML or AML transformed myelodysplastic syndrome (MDS) with FAB classification other than M3 as proven by bone marrow aspiration. * Age ≥60 years. * ECOG performance status of 0-2 (Karnofsky \>60%). * Adequate renal functions: Serum Creatinine \< 2 times the upper limit of normal (ULN). * Adequate hepatic function: serum AST and ALT ≤ 3 x ULN. * Patients with reproductive potential must use an effective contraceptive method through the study. Patients must receive contraceptive and/or fertility counseling prior to entering the study, i.e., information on sperm banking, etc.
Exclusion criteria
* Patients receiving any other investigational agents. * Symptomatic CNS involvement. * History of pancreatitis or active alcohol abuse. * Histologic diagnosis of FAB M3 AML. * Life expectancy of less than 1 month. * Patient receives Myelotarg (ozogamicin gemtuzumab). * Use of hematopoietic growth factors such as G-CSF within 1 week prior to treatment initiation. * Pregnant or lactating females. * Patient has known human immunodeficiency virus (HIV) infection or known HIV-related malignancy; Patient has active hepatitis A, B or C infection. * Active, uncontrolled, systemic infection considered opportunistic, life threatening, or of clinical significance at the time of treatment, or any severe concurrent disease which, in the opinion of the investigator, would make the patient inappropriate for trial entry. * The patient has had congestive heart failure - New York Heart Association (CHF-NYHA) grade II or higher, and/or myocardial infarction within the last 12 months, or any cardiac disorder which, in the opinion of the Investigator, could put the patient at risk of clinically relevant arrhythmia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time (days) to reach platelet counts ≥20,000/µl after first induction course and post-remission chemotherapy courses. | Continously during study and maximum 6 months from the beginning of the study. |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in bone marrow blasts from baseline throughout the study period. | Continously during study and maximum 6 months from the beginning of the study. |
| Time (days) to reach platelets counts ≥50,000/µl after first induction course and subsequent post-remission chemotherapy courses. | Continously during study and maximum 6 months from the beginning of the study. |
| Time (days) to reach platelets counts ≥100,000/µl after first induction course and subsequent post-remission chemotherapy courses. | Continously during study and maximum 6 months from the beginning of the study. |
| To assess safety and tolerability of AS101. | Continously during study and maximum 6 months from the beginning of the study. |
| To evaluate the number of platelet transfusions through the study period. | Continously during study and maximum 6 months from the beginning of the study. |
| To measure the incidence and severity of bleeding events using the World Health Organization (WHO) Bleeding Scale, during the treatment and follow-up periods. | Continously during study and maximum 6 months from the beginning of the study. |
| To assess a correlation between VLA-4 expressions level of leukemia blasts in vitro and the response to treatment in terms of blasts percent. | Continously during study and maximum 6 months from the beginning of the study. |
| Time (days) to reach the maximum platelets counts after chemotherapy courses throughout the study period. | Continously during study and maximum 6 months from the beginning of the study. |
Countries
Israel
Outcome results
None listed